„We are very pleased with the new fee schedules and more importantly, the levels will be seen as appropriate by clinicians to support the expanded use of the Nevisense test for early melanoma detection at point of care. For SciBase this is a critical decision that paves the way for further US expansion – both… SciBase receives increased US Medicare fee schedules for the Nevisense melanoma test weiterlesen
„We are excited to integrate the Nevisense test during routine skin exams in our Freehold and Verona, New Jersey offices and offer our patients the latest technology for the earliest possible detection of melanoma. Melanoma is the deadliest form of skin cancer, but when detected early, treatment has a nearly 100% cure rate. Early testing… SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase announces outcome of rights issue of shares weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase publishes prospectus in connection with fully guaranteed rights issue weiterlesen
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN… SciBase resolves on a fully guaranteed rights issue of approximately SEK 79.6 million weiterlesen
The ORIGINS Project follows the progress of pregnant women, their partners and babies for the first five years of the baby’s life, and beyond, based on an increasing understanding that an individual’s lifetime health and disease may be programmed at a very early stage – even while a child is still in the womb. The… Nevisense for skin barrier evaluation included in large Australian birth cohort study weiterlesen
The focus will be on SciBase’s recently announced collaboration with Johnson & Johnson Consumer Health to develop a unique AI-based screening tool to predict the development of a common type of eczema known as atopic dermatitis in infants. SciBase CEO Simon Grant will give an in-depth picture of the potential that exists in the skin… SciBase invitation to a webinar on November 10 at 11:00 CET weiterlesen
Link to press release from November 7th: http://investors.scibase.se/en/scibase-announces-collaboration-to-detect-skin-barrier-dysfunction-in-infants Simon Grant, CEO of SciBase comment on the skin barrier segment and the collaboration with Johnson & Johnson Consumer Health Inc. can be found through the link below: Link to CEO comment: https://players.brightcove.net/1555966121001/default_default/index.html?videoId=6315110856112 For more information around skin barrier and SciBase: https://barrier.scibase.com/ For more information, please contact:… SciBase CEO Simon Grant gives a comment regarding the collaboration with Johnson & Johnson Consumer Health weiterlesen
The goal of the collaboration is to develop and validate an AI-based solution that detects skin barrier dysfunction and may be able to predict an infant’s risk of developing atopic dermatitis. The method will be based on SciBase’s Electrical Impedance Spectroscopy (EIS) technology and specifically for the portable Nevisense Go device. The collaboration will start… SciBase announces collaboration to detect skin barrier dysfunction in infants weiterlesen
The article describes Electrical impedance spectroscopy (EIS) as a recently emerged promising alternative measurement of skin barrier function. EIS is a non-invasive indicator of epidermal integrity, rapidly measuring the skin’s resistance to the flow of alternating imperceptible currents. Considering the likely differences in cell size and orientation between typical and abnormal skin, EIS has been… New article discusses EIS as a potential clinical measure of skin barrier integrity weiterlesen
